Institution
Bharathidasan University
Education•Tiruchchirappalli, Tamil Nadu, India•
About: Bharathidasan University is a education organization based out in Tiruchchirappalli, Tamil Nadu, India. It is known for research contribution in the topics: Hydrogen bond & Ring (chemistry). The organization has 3947 authors who have published 6342 publications receiving 108867 citations. The organization is also known as: BDU.
Topics: Hydrogen bond, Ring (chemistry), Catalysis, Crystal, Single crystal
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this article, it was shown that for any positive integer n⩾3, there exist two equienergetic graphs of order 4n that are not cospectral.
919 citations
••
TL;DR: In this article, a plant extract, Mentha piperita (Lamiaceae), was used for the synthesis of nanoparticles and the nanoparticles were characterized by FTIR, SEM equipped with EDS.
756 citations
••
TL;DR: These studies establish NAB2-STAT6 as the defining driver mutation of SFT and provide an example of how neoplasia can be initiated by converting a transcriptional repressor of mitogenic pathways into an transcriptional activator.
Abstract: A 44-year old woman with recurrent solitary fibrous tumor (SFT)/hemangiopericytoma was enrolled in a clinical sequencing program including whole-exome and transcriptome sequencing. A gene fusion of the transcriptional repressor NAB2 with the transcriptional activator STAT6 was detected. Transcriptome sequencing of 27 additional SFTs identified the presence of a NAB2-STAT6 gene fusion in all tumors. Using RT-PCR and sequencing, we detected this fusion in all 51 SFTs, indicating high levels of recurrence. Expression of NAB2-STAT6 fusion proteins was confirmed in SFT, and the predicted fusion products harbor the early growth response (EGR)-binding domain of NAB2 fused to the activation domain of STAT6. Overexpression of the NAB2-STAT6 gene fusion induced proliferation in cultured cells and activated the expression of EGR-responsive genes. These studies establish NAB2-STAT6 as the defining driver mutation of SFT and provide an example of how neoplasia can be initiated by converting a transcriptional repressor of mitogenic pathways into a transcriptional activator.
626 citations
••
TL;DR: The mutations present in advanced cancers can be identified by integrative high-throughput sequencing to enable biomarker-driven clinical trials and, ultimately, treatment and the authors tested this approach by extensively characterizing cancers in several patients and then convening a Sequencing Tumor Board of experts to determine the appropriate treatment.
Abstract: Individual cancers harbor a set of genetic aberrations that can be informative for identifying rational therapies currently available or in clinical trials. We implemented a pilot study to explore the practical challenges of applying high-throughput sequencing in clinical oncology. We enrolled patients with advanced or refractory cancer who were eligible for clinical trials. For each patient, we performed whole-genome sequencing of the tumor, targeted whole-exome sequencing of tumor and normal DNA, and transcriptome sequencing (RNA-Seq) of the tumor to identify potentially informative mutations in a clinically relevant time frame of 3 to 4 weeks. With this approach, we detected several classes of cancer mutations including structural rearrangements, copy number alterations, point mutations, and gene expression alterations. A multidisciplinary Sequencing Tumor Board (STB) deliberated on the clinical interpretation of the sequencing results obtained. We tested our sequencing strategy on human prostate cancer xenografts. Next, we enrolled two patients into the clinical protocol and were able to review the results at our STB within 24 days of biopsy. The first patient had metastatic colorectal cancer in which we identified somatic point mutations in NRAS, TP53, AURKA, FAS, and MYH11, plus amplification and overexpression of cyclin-dependent kinase 8 (CDK8). The second patient had malignant melanoma, in which we identified a somatic point mutation in HRAS and a structural rearrangement affecting CDKN2C. The STB identified the CDK8 amplification and Ras mutation as providing a rationale for clinical trials with CDK inhibitors or MEK (mitogenactivated or extracellular signal–regulated protein kinase kinase) and PI3K (phosphatidylinositol 3-kinase) inhibitors, respectively. Integrative high-throughput sequencing of patients with advanced cancer generates a comprehensive, individual mutational landscape to facilitate biomarker-driven clinical trials in oncology.
608 citations
••
TL;DR: This paper comprehensively reviews the significance of plant genetic diversity (PGD) and PGR especially on agriculturally important crops; risk associated with narrowing the genetic base of current commercial cultivars and climate change; analysis of existing PGD analytical methods in pregenomic and genomic era; and modern tools available for PGD analysis in postgenomic era.
Abstract: The importance of plant genetic diversity (PGD) is now being recognized as a specific area since exploding population with urbanization and decreasing cultivable lands are the critical factors contributing to food insecurity in developing world. Agricultural scientists realized that PGD can be captured and stored in the form of plant genetic resources (PGR) such as gene bank, DNA library, and so forth, in the biorepository which preserve genetic material for long period. However, conserved PGR must be utilized for crop improvement in order to meet future global challenges in relation to food and nutritional security. This paper comprehensively reviews four important areas; (i) the significance of plant genetic diversity (PGD) and PGR especially on agriculturally important crops (mostly field crops); (ii) risk associated with narrowing the genetic base of current commercial cultivars and climate change; (iii) analysis of existing PGD analytical methods in pregenomic and genomic era; and (iv) modern tools available for PGD analysis in postgenomic era. This discussion benefits the plant scientist community in order to use the new methods and technology for better and rapid assessment, for utilization of germplasm from gene banks to their applied breeding programs. With the advent of new biotechnological techniques, this process of genetic manipulation is now being accelerated and carried out with more precision (neglecting environmental effects) and fast-track manner than the classical breeding techniques. It is also to note that gene banks look into several issues in order to improve levels of germplasm distribution and its utilization, duplication of plant identity, and access to database, for prebreeding activities. Since plant breeding research and cultivar development are integral components of improving food production, therefore, availability of and access to diverse genetic sources will ensure that the global food production network becomes more sustainable. The pros and cons of the basic and advanced statistical tools available for measuring genetic diversity are briefly discussed and their source links (mostly) were provided to get easy access; thus, it improves the understanding of tools and its practical applicability to the researchers.
542 citations
Authors
Showing all 3992 results
Name | H-index | Papers | Citations |
---|---|---|---|
Vineet Kumar | 123 | 1241 | 73909 |
Savarimuthu Ignacimuthu | 64 | 498 | 17752 |
Eringathodi Suresh | 57 | 444 | 11683 |
M. Michael Gromiha | 56 | 352 | 10617 |
M. Lakshmanan | 54 | 533 | 13357 |
Helen Stoeckli-Evans | 54 | 674 | 12869 |
Arivalagan Pugazhendhi | 53 | 362 | 8975 |
Gopalan Rajaraman | 51 | 255 | 7459 |
Kyo Han Ahn | 50 | 186 | 7334 |
Anthony Linden | 49 | 870 | 11140 |
Annamalai Subramanian | 49 | 95 | 6021 |
Mallayan Palaniandavar | 47 | 155 | 7705 |
K. P. Ramesh | 47 | 391 | 7504 |
M. K. Daniel | 42 | 204 | 12033 |
Joseph Selvin | 40 | 158 | 5131 |